Milatuzumab
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].
Product Specifications
CAS Number
899796-83-9
Product Name Alternative
HLL1; MEDI-115
UNSPSC
12352203
Target
CD74
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/milatuzumab.html
Purity
99.39
Solubility
10 mM in DMSO
Smiles
[Milatuzumab]
Molecular Weight
(145.66 kDa)
References & Citations
[1]Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117 (17) :4530-41.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A06628-2-HRP 100 µg/Vial
Anti-PRAME Picoband® Antibody, HRP Conjugate
Sign In for Pricing
View Details 